Corbus Pharmaceuticals
Price & Volume
Stats
See moreOpen | $7.67 |
Previous Close | $7.52 |
Day Range | $7.55-$7.67 |
52W Range | $4.64-$61.90 |
Market Cap | $91.9M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | -100% |
Gross Profit (12 Mos) | -$32.2M |
Diluted EPS | -$3.68 |
News
See moreYahoo Finance • last month
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Yahoo Finance • 3 months ago
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
Yahoo Finance • 3 months ago
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
Yahoo Finance • last year
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
About
CEO | Dr. Yuval Cohen Ph.D. |
Address | 500 River Ridge Drive, Norwood, MA, United States, 02062 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 28 |
